Pharmaceutical Executive Top 50 Pharma Companies Report

40

PHARMACEUTICAL EXECUTIVE PHARMACEUTICAL EXECUTIVE

Will the recent wave of megamergers and a slow revival of biotech financing be enough to counter a looming storm surge of patent expirations? US health reform is the next big game-changer, as companies seek a balance between earning profits and placating a restive new breed of payers and the ever-expectant patient By Jerry Cacciotti and Patrick Clinton

Sponsored by www.dsm.com

41

MAY 2011 www.pharmexec.com

Revenue Distribution o Top 50 10%

8%

Top 10 accounts or $352.5 billion in sales, which is 59.40% o total revenues o the Top 50

6%

Top 20 accounts or $483.8 billion in sales, which is 81.53% o total revenues o the Top 50

4%

2%

0%

Pzer Sano-Aventis Merck GlaxoSmithKline Johnson AstraZeneca Bristol-Myers & Eli y Johnson Lilly Abbott Amgen Squibb Boehringer Bayer Takeda Novo k Ingelheim Daiichi Nordisk Astellas Sankyo Eisai Gilead Sciences International Servier Mitsubishi Menarini Genzyme Tanabe Allergan Forest Celgene BiogenShire Warner Idec Alcon Cephalon Chilcott Watson Kyowa Lundbeck Dainippon Hakko Shionogi Sumitomo Actavis Hospira Nycomed Apotex Sta iBaxter lMylan i e i iKirin rNovartis t b Teva rChugai t CSL t kRoche L UCB k i oMerck A KGaA BOtsuka l o t t i s t i s r c i s i r a e d t e x d a a a e r d a i m i s l i n m e g a s k y k a e n e d e c h e s n a l a n v t h e l n e e c a s o n L b e v a g e n y b r a n e s S o n s o n e c a i e g i r e c o n c o r n m o o g a v i C z e r l s i i l i l i c c e u n e a p r C b y  G y d a u l o u T m B k l U t s l g I S A i o o n t s o m p t a l h a a t b K i i o M e r h a n n a z l e r o K e n h n l i b q P o v a v e M e R o h t e a n E K i e n a t d o t h i c a e h o r s n h F n A e c A S l A p E C e S t S T O T A k n Z S e o W m k u S A H o y i a J C e g N A i C g N  c S c r n i M G e A u k s n r r N r m C o r I h L h o a t & i e e t e v i c e S s i s H n S n o B y i o M e a d I n e r N o a r n A o n b a x a g a M u l r S p o i t e D s l l a i n W t s r o w i p o G x i G h n t y h i n M a K a e i s J o B B r D B o

he Pharm Exec 50 ranks the world’s largest pharmaceutical companies by global sales of prescription drugs—a key indicator of market change. After last year’s storm of activity, the 50 set a more placid pace, as major players worked on integrating blockbuster mergers and licked their wounds after the latest round of Phase III failures. Late-phase problems are nothing new, and drug candidates can come back from them, but there was something particularly heartbreaking about the recent crop of dead ends, given the huge unmet medical need associated with these therapies: Pzer’s Dimebon and Lilly’s Semagacestat for Alzheimer’s, Merck’s vicriviroc for HIV, and Roche’s ocrelizumab for rheumatoid arthritis, to name just a few. Change was most visible on the macro level. The list of t he top 10 companies was shaken up a bit, with Novartis passing Sano-Aventis to move into second place, and Merck jumping from seventh to fourth. It was also the rst year the top company crossed the $50 billion mark in sales of prescrip-

T

tion drugs—as Pzer, fueled by its acquisition of Wyeth, grew from $45.4 billion in Rx sales to $58.5 billion. Meanwhile, consolidation in the ranks continues to place a premium on size and scale: This was the rst year that it took $2 billion in Rx revenues to join the 50. As recently as 10 years ago, you could make the list with revenues of only $500 million. Overall, the 50 accounted for $593.4 billion in human prescription drug sales in 2010. That represents an increase of nearly 8 percent from 2009, when the total was $550.5 billion. But among the top 10, there was slightly better growth. This year’s group grew its Rx revenues from $319.4 billion in scal 2009 to $352.5 last year—an increase of over 10 percent. A good percentage of that growth was fueled by mergers and acquisitions. In addition to Pzer and its 29 percent increase, big gainers included Merck (58 percent growth after its merger with Schering Plough) and Abbott (up nearly 28 percent in the wake of its acquisitions of Solvay and Pira-

mal). But the biggest single-year bump came at a much smaller company: The Irish rm Warner Chilcott last year acquired the pharmaceutical business of Procter & Gamble, including the billion-dollar drug Actonel, and raised its Rx revenues a whopping 111 percent to $2.9 billion. Looming over the year—and the decade—is the shadow of US healthcare reform. Many in pharma feel they have dodged the bullet of new regulation and stand to gain as a projected 30 million previously uninsured Americans nally obtain insurance coverage for healthcare. But the Patient Protection and Affordable Care Act is not the end of the discussion—it’s more like the beginning of an avalanche. The economic forces it sets in motion today will be playing out for payers, patients, providers, and pharma for the foreseeable future, changing the way care is delivered and paid for, creating numerous business threats, but, with luck, ending up with the possibility of getting a better alignment between helping the patient and earning a prot.


d e d n u o r e r a s e r u g i F *

42

PHARMACEUTICAL EXECUTIVE

2011 Rank

Company HQ [website]

2010 Rx Sales

1

Pfzer

2

Novartis

3

Sanof-Aventis

4

Basel, Switzerland [novartis.com]

[sano-aventis.com]

Merck Whitehouse Station, New Jersey [merck.com]

5

Roche

6

GlaxoSmithKline

7

AstraZeneca

8

Johnson & Johnson

9

Eli Lilly

10

Abbott

[9.2%]

$7,100

Diovan/Co-Diovan [6.1] Gleevec/Glivec [4.3] Lucentis [1.5]

$40.3

[–4.1%]

$5,147

Lantus [4.7] Lovenox [3.7] Taxotere [2.8]

$39.8

[58.0%]

$11,000

Singulair [5.0] Remicade [2.7] Januvia [2.4]

[4.1%]

$8,612

Avastin [6.8] MabThera/Rituxan [6.7] Herceptin [5.7]

$6,126

Seretide/Advair [7.9] Pandemic Flu Vaccine [1.8] Flixotide/Flovent [1.2]

$4,200

Crestor [5.7] Nexium [5.0] Seroquel [4.1]

$4,432

Remicade [4.6] Procrit [1.9] Risperdal [1.5]

$4,880

Zyprexa [5.0] Cymbalta [3.5] Alimta [2.2]

$3,724

Humira [6.5] Trilipix/TriCor [1.6] Kaletra [1.3]

$22.4

New Brunswick, New Jersey [jnj.com]

$21.1

Indianapolis, Indiana [lilly.com]

$19.9

Abbott Park, Illinois [abbott.com]

Sources: corporate data (10K’s, annual reports, etc.) and

$42.0

$33.3

London, England [astrazeneca.com]

Pharm Exec

estimates

[USD billions]

Lipitor [10.7] Enbrel [3.3] Lyrica [3.1]

$36.2

Brentord, England [gsk.com]

2010 Top-Selling Drugs

(USD millions)

$9,413

$39.1

Basel, Switzerland [roche.com]

2010 R&D spend

[28.9%]

$58.5

New York, New York [pzer.com]

Paris, France

(USD

billions) [% change from 2009]

[–4.2%]

[1.4%]

[–0.4%]

[5.4%]

[27.7%]

N/A = Not Available/Not Applicable

* Estimate

Figures are rounded

How the listings were compiled: Companies in the Pharm Exec 50 are ranked according to global human prescription drug sales. As ar as company documentation allows, generics and vaccines are included; over-the-counter products, royalties, and contract manuacturing revenue are not. In most cases, numbers are taken rom annual reports or SEC lings or the scal year that ended in 2010. For most American and European companies, that means the year ending Dec. 31, 2010; or many Japanese companies, it means the year ending March 31, 2010. In the case o private companies that do not report results, we have made estimates based on available data, including IMS reports. For companies that report in currencies other than US dollars, we have converted their numbers using the midpoint average interbank rate or the last day o the scal year. Some charts that accompany this article are based on numbers rom IMS Health. These are based on a dierent methodology and will not be consistent with the gures we have compiled rom nancial lings. Percentage growth gures should be treated with caution, because they can be aected by fuctuating exchange rates.


44


Global Pharma Sales by Region Market Share

Region

USD in Billions

Growth from 2009

North America

334.8

Europe

29.2%

230.7

Asia/Africa/Australia

1.8%

98.1

Japan

12.4%

3.2% 13.3%

85.7

0.4%

Latin America 42.0

42.3%

16.3%

Worldwide Totals: $791.4

10.8% 5.3%

4.2%

S A D I M , h t l a e H S M I : e c r u o S

Sales represent audited market or pharma products only (Dec. 2009–Dec 2010) IMS gures do not account or o-invoice discounts/rebates and can vary rom reported mr sales

Top 25 US Pharma Products by Sales Product Nexium

2

Plavix

3

Advair Diskus Abilify

5 6

Seroquel

7

Singulair Crestor

8

9

Epogen

10

Remicade

11

12

Enbrel

Cymbalta

13

Avastin

14

Oxycontin

15

16

Neulasta

17

Zyprexa Humira

18 19

Lexapro

20

Rituxan

21 22

Aricept

Lovenox

23 24 25

Actos

Atripla

Copaxone

Spiriva Handihaler

2009 7.2 6.3 6.1

Lipitor

1

4

2010

7.6

2010: $307.4

-5.26

6.3 5.6

4.7 4.7 4.6 4.0 4.4 4.2 4.1 3.7 3.8 3.0 3.5 3.4 3.3 3.2 3.3 3.2 3.3 3.3 3.2 2.8 3.1 3.0 3.1 2.9 3.0 3.0 3.0 2.7 2.9 2.5 2.8 2.8 2.8 2.6 2.5 2.3 2.3 2.8 2.2 1.9 2.2 1.7 2.0 1.7

TOTAL US SCRIP MARKET:

% Change FLAT 8.92 FLAT 15.00 4.76 10.81 26.66 2.94 3.13 3.13 FLAT 14.29 3.33 6.90 FLAT 11.11 16.00 FLAT 7.69 8.7 -17.86 15.79 29.41 17.65

2009: $300.3

2.36% Figures (rounded) in US billions


h t l a e H S M I : e c r u o S

46


2011 Rank


11

Bristol-Myers Squibb

12

Teva

13

Amgen

14

Bayer

15

Takeda

16

2010 Rx Sales

$19.5

New York [bms.com]

Petach Tikva, Israel [tevapharm.com]

Thousand Oaks, Caliornia [amgen.com]

Leverkusen, Germany [bayer.com]

Osaka, Japan [takeda.com]

Boehringer Ingelheim Ingelheim, Germany [boehringer-ingelheim.com]

17

Novo Nordisk

18

Astellas

19

Daiichi Sankyo

20

Eisai

Bagsvaerd, Norway [novonordisk.com]

Tokyo, Japan [astellas.com]

Pharm Exec

estimates


(USD Millions)

[USD billions]

$3,566

$16.1

[16.0%]

$933

$14.7

[1.8%]

$2,894

Neulasta/Neupogen [4.8]

$14.5

[–3.6%]

$2,320

Betaeron/Betaseron [1.6]

$14.2

[–0.1%]

$3,198

Actos/Glustin [4.2]

$12.9

[–10.8%]

$3,056

Spiriva [3.8]

$10.8

[9.9%]

$1,709

NovoRapid [2.1]

$10.5

[6.0%]

$2,109

Progra [1.9]

[20.0%]

$2,124

Olmesartan [2.6]

[8.0%]

$1,932

Aricept [3.5]

$8.4

Tokyo, Japan [eisai.com]

2010 R&D spend

[3.6%]

$9.8

Tokyo, Japan [daiichisankyo.com]


(USD


Copaxone [2.9]



Plavix [6.7]

* Estimate

Figures are rounded

48


Top 20 Therapeutic Classes by Spending Product

2010

2009

% Change

22.3 Oncologics 19.3 18.1 2 Respiratory Agents 18.8 18.6 3 Lipid Regulators 16.9 15 4 Antidiabetes 16.1 14.7 5 Antipsychotics 11.9 14.1 6 Antiulcerants 11.6 11.5 7 Antidepressants 10.6 9.7 8 Autoimmune Diseases 9.2 8.2 9 HIV Antivirals 8.7 8.6 10 Angiotensin II 8.4 8.0 11 Narcotic Analgesics 7.2 6.3 12 ADHD 7.1 6.5 Platelet Aggregation Inhibitors 13 6.1 6.3 14 Erythropoietins 5.7 4.9 15 Multiple Sclerosis 5.6 6.9 16 Antiepileptics 5.0 4.6 17 Vaccines (Pure, Combo, Other) 18 Hormonal Contraceptives 4.8 4.7 19 Anti-Alzheimers 4.5 4.0 20 Immunostimulating Agents 4.2 4.1 1


2010: $307.4

21.5

3.72 6.63 1.08 12.66 9.52 -15.60 0.87 9.28 12.19 1.16 5.00 14.28 9.23 -3.17 16.33 -18.84 8.69 2.13 12.5 2.44

2009: $300.3


2.36%

Figures (rounded) in USD billions Therapy Class dened using ATC-dened product groups and synthesized based on proprietary IMS Health denitons Immunostimulating Agents excludes intererons

Top 20 Therapeutic Classes by Prescriptions Class Lipid Regulators 2 Antidepressants 3 Narcotic Analgesics 4 Beta Blockers (Plain & Combo) 5 Ace Inhibitors 6 Antidiabetes 7 Respiratory Agents 8 Anti-ulcerants 9 Diuretics 10 Antiepileptics 11 Tranquilizers 12 Thyroid Preps 13 Calcium Antagonists (Plain & Combo) 14 Antirheumatics 15 Hormonal Contraceptives 16 Angiotensin II 17 Penicillins 18 Macrolides & Similar Type 19 Vitamins & Minerals 20 Hypnotics & Sedatives 1


2010

2009

255.4 253.6 244.3 191.5 167.8 168.7 165.7 165.0 159.0 153.3 152.4 147.1 145.7 131.0 131.7 121.7 115.3 108.6 104.0 107.2 105.3 97.9 94.9 95.0 92.5 92.3 93.9 83.7 84.4 76.1 76.6 73.9 69.3 71.9 69.8 66.0 65.5

2010: 3,995.2

% Change

249.7 246.1 241.0

2.28 3.05 1.37 14.12 1.81 3.77 0.59 0.96 -0.53 5.55 4.42 1.8 3.16 2.70 -1.70 -0.83 -0.65 6.64 3.01 0.76

2009: 3,949.2

1.16%

Rx gures (rounded) in millions; Therapy classes dened using ATC dened product groups and synthesized based on proprietary IMS Health denitions



50


2011 Rank


21

Merck KGaA

22

Gilead Sciences

23

Baxter International

24

Mylan

25

Servier

26

Chugai

27

Mitsubishi Tanabe

28

Menarini

29

Genzyme

30

Allergan

2010 Rx Sales

Darmstadt, Germany [merck.de]

Foster City, Caliornia [gilead.com]

Deerfeld, Illinois [baxter.com]

Canonsburg, Pennsylvania [mylan.com]

Neuilly-sur-Seine [servier.com]

Tokyo, Japan [chugai-pharm.co.jp]

Osaka, Japan [mt-pharma.co.jp]

Florence, Italy [menarini.com]

Cambridge, Massachusetts [genzyme.com]

Irvine, Caliornia [allergan.com]


(USD


Pharm Exec

estimates

2010 R&D spend


(USD Millions)

[USD billions]

$7.8

[–0.4%]

$1,547

Rebi [2.2]

$7.4

[14.2%]

$1,073

Atripla [3.0]

$5.6

[1.3%]

$915

Advate [1.7]

$5.2

[7.5%]

$282

EpiPen [0.3]

$4.9

[6.6%]

$1,226

$4.6

[1.3%]

$671

Avastin [0.6]

$4.4

[2.4%]

$897

Remicade [0.5]

$4.0*

[0.2%]

N/A

Migard/Allegro [0.1*]

$4.0

[2.3%]

$847

Cerezyme [0.7]

$4.0

[7.9%]

$805

Botox [1.4]



Coversil [1.5*]

* Estimate

Figures are rounded

51

MAY 2011 www.pharmexec.com

Top 25 Corporations by U.S. Sales Product 1 Pfizer 2 Merck 3

AstraZeneca 4 Novartis 5 Lilly 6 Roche 7 Teva 8 GlaxoSmithKline 9 Johnson & Johnson 10 Amgen 11 Abbott 12 Sanofi-Aventis 13 Bristol-Myers Squibb 14 Boehringer Ingelheim 15 Takeda 16 Forest 17 Mylan 18 Gilead 19 Otsuka America 20 Eisai 21 Novo Nordisk 22 Watson 23 Nestle S.A. 24 Purdue 25 Galen Holdings

2010

2009

% Change

26.2 18.8 18.3 15.7 13.2 14.3 13.2 13.8 14.2 13.7 12.1 13.6 15.0 12.9 12.8 12.7 12.5 10.8 10.6 10.4 11.2 9.7 9.0 6.4 7.6 6.0 7.9 4.7 4.4 4.7 3.9 4.7 3.9 4.6 4.0 4.6 4.4 4.5 3.7 3.3 3.2 3.2 2.8 3.2 3.0 3.0 2.8


27.8

-5.75 -5.05

19.8 18.3

FLAT 18.94 8.33 -2.82 13.22 -9.33 0.78 1.60 1.89 -7.14 7.77 -15.79 -24.05 6.82


20.51 20.51 15.00 4.54 21.62 3.12 14.28 6.67 7.14

2010: $307.4

2009: $300.3

2.36% Figures (rounded) in billions

Top 25 Corporations by Prescriptions Corporation Teva Mylan 3 Novartis 4 Pfizer 5 Watson 6 Endo 7 Lupin 8 Merck 9 Amneal 10 AstraZeneca 11 Covidien 12 GlaxoSmithKline 13 Boehringer Ingelheim 14 Actavis U.S. 15 Dr Reddy 16 Abbot 17 Zydus 18 Lilly 19 West Ward 20 Forest 21 Ranbaxy 22 Bristol-Myers Squibb 23 Par 24 Sanofi-Aventis 25 Aurobindo

2010

2009

1

2

379.9

265.3 240.9 242.0 265.7 233.6 235.1 141.0 114.5 134.0 96.2 104.2 123.3 97.9 67.5 86.8 93.8 80.2 91.2 72.6 78.2 71.1 72.4 68.1 71.1 63.5 73.5 58.1 61.0 53.9 34.9 49.5 49.8 45.2 34.3 44.3 46.2 42.5 31.0 42.2 44.1 40.2 48.2 40.0 42.1 39.7 38.9


% Change

639.3 347.2

629.8 -8.92 -0.64

1.51 9.41 10.13 23.14

39.29

-15.49

45.04

-7.46 -12.06 -7.16 -1.79 -4.22 -13.60 -4.75

54.44

-0.60

31.78

-4.11

37.09

-4.31 -16.60 -4.99

2010: 3,995.2

2.06

2009: 3,949.2


1.16% Figures (rounded) in millions

Top 25 U.S. Pharma Products by Prescriptions Product hydrocodone/acetaminophen 2 simvastatin 3 lisinopril 4 levothyroxine sodium 5 amlodipine besylate 6 omeprazole (RX) 7 azithromycin 8 amoxicillin 9 metformin HCL 10 hydrochlorothiazide 11 alprazolam 12 Lipitor 13 furosemide 14 metoprolol tartrate 15 zolpidem tartrate 16 atenolol 17 sertraline HCL 18 metoprolol succinate 19 citalopram HBR 20 warfarin sodium 21 oxycodone/acetaminophen 22 ibuprofen (Rx) 23 Plavix 24 gabapentin 25 Singulair

1


2010 131.2 94.1 87.4 70.5 66.0 57.2 51.3 53.4 45.4 52.6 53.8 52.3 52.4 48.3 44.3 47.8 47.9 46.3 43.9 45.3 51.7 43.4 43.5 38.9 41.1 38.0 35.1 36.3 39.3 35.7 34.2 33.0 26.9 32.1 27.1 32.0 31.6 31.9 30.2 31.1 30.3 29.5 29.9 29.3 25.4 28.7 28.6

2010: 3,995.2

2009

% Change 128.2

2.34

83.8 82.8

12.29 5.56 6.82 11.5 17.62 -2.23 -0.19 9.03 -0.21 5.47 -12.38 -0.23 -5.35 8.26 -7.63 4.38 22.68 18.45 1.27 5.63 2.64 -1.34 15.35 0.35

2009: 3,949.2


1.16% Figures (rounded) in millions


52


2011 Rank


31

Forest

32

CSL

33

UCB

34

Otsuka

35

Celgene

36

Biogen Idec

37

Shire

38

Alcon

39

Warner Chilcott

40

Cephalon

2010 Rx Sales

$3.9

New York, New York [rx.com]

Victoria, Australia [csl.com.au]

Brussels, Belgium [ucb.com]

Summit, New Jersey [celgene.com]

Weston, Massachusetts [biogenidec.com]

Dublin, Ireland [shire.com]

Hünenberg, Switzerland [alcon.com]

Dublin, Ireland [wcrx.com]

Frazer, Pennsylvania [cephalon.com]

Pharm Exec

estimates

2010 R&D spend


(USD Millions)

[USD billions]

[7.4%]

$1,054

$3.8

[–3.6%]

$272

$3.7

[–4.0%]

$1,044

Keppra [1.2]

[–46.1%]

N/A

Abiliy [4.5*]

$3.5

[36.7%]

$1,128

Revlimid [2.5]

$3.5

[10.1%]

$1,249

Avonex [3.5]

$3.1

[16.1%]

$662

Vyvanse [0.6]

$3.1

[14.5%]

$747

Glaucoma products [1.3]

$2.9

[111.0%]

$147

Actonel [1.0]

$2.8

[28.3%]

$440

Provigil [1.1]

$3.6*

Tokyo, Japan [www.otsuka.co.jp/en/]


(USD


N/A [N/A]



Lexapro [2.3]

* Estimate

Figures are rounded

54


Top US Patent Expiries Rank 1 2 3 4 5 6 7 8 9 10 11

Product/Company LIPITOR/Pzer ADVAIR DISKUS/GSK ZYPREXA/Eli Lilly LEVAQUIN/Ortho-McNeil XALATAN/Pzer FEMARA/Novartis ZYPREXA ZYDIS/Eli Lilly ADVAIR HFA/GSK PATANOL/Alcon PATADAY/Alcon VIVELLE-DOT/Novogyne

LOE date

2010 Sales

Q4 2011 Q3 2011 Q4 2011 Q2 2011 Q1 2011 Q2 2011 Q4 2011 Q3 2011 Q2 2011 Q2 2011 Q1 2011

Total Rx 2010 7,244.1

45.8

4,711.4

19.7

2,957.6

5.3 10.9 6.9 1.3 0.4 1.1 2.3 2.1 3.2

1,522.4 710.8 681.6 331.1 254.6 241.1 215.0 215.0


Sales gures (rounded) in USD millions; Rx gures rounded

LOE = Loss o Exclusivi ty

Top 20 Global Therapy Classes by Sales Product 1 Oncologics 2 Lipid Regulators 3 Respiratory Agents 4 Antidiabetics 5 Antiulcerants 6 Angiotensin II Antagonists 7 Antipsychotics 8 Autoimmune Agents 9 Antidepressants 10 HIV Antivirals 11 Platelet Aggreg. Inhibitors 12 Antiepileptics 13 Narcotic Analgesics 14 Cephalosporins & Combs 15 Erythropoietin Products 16 Vaccines 17 Multiple Sclerosis 18 Antirheumatics (Non-steroid ) 19 Hormonal Contraception 20 Calcium Antagonists

2010

% Change 56.0

6.7 2.0 7.0

36.4 35.8 34.4

12.2

27.2 26.6 25.4

-6.7 4.5 9.0

20.7 20.2

14.7 3.4

15.4 14.6 12.6 12.0 11.6 10.6 10.5 9.8 9.8 9.5 9.2

13.2 1.5 -3.3 6.4 5.8 -1.8 3.5 13.9 3.6 5.3 -8.8

TOTAL US SCRIP MARKET: 2010: $408.3

2009: $384.9

S A D I M , h t l a e H S M I : e c r u o S

6.10%

Figures (rounded) in USD billions (Dec 2009–Dec 2010) Sales represent audited market or pharma products only IMS gures do not account or o-invoice discounts/rebates and can vary rom reported mr sales

Top 20 Leading Global Products by Sales Product Lipitor (atorvastatin) Plavix (clopidogrel) 3 Seretide (fluticasone/salmeterol) 4 Nexium (esomeprazole) 5 Seroquel (quetiapine) 6 Crestor (rosuvastatin) 7 Enbrel (etanercept) 8 Remicade (infliximab) 9 Humira (adalimumab) 10 Zyprexa (olanzapine) 11 Avastin (bevacizumab) 12 Singulair (montelukast) 13 Abilify (aripiprazole) 14 Mabthera (rituximab) 15 Lantus (insulin glargine) 16 Aricept (donepezil) 17 Actos (pioglitazone) 18 Lovenox (enoxaparin sodium) 19 Herceptin (trastuzumab) 20 Diovan (valsartan)

2010

% Change 12,656.1

1

2


8,816.5 8,468.6 8,361.5 6,815.6 6,796.3 6,167.2 6,038.6 5,959.5 5,736.3 5,532.2 5,465.4 5,430.3 5,033.2 4,685.3 4,432.1 4,317.3 4,282.0 4,165.1 4,156.4

2010: $123,315.5

-6.2 -3.4 4.4 1.3 13.2 24 5.2 10.3 19.7 6.6 16.3 7.8 16.7 8.5 3.9 -5.3 6.7 3.5

2009: 116,221.7

Sales represent audited market or pharma products only

6.10% Increase

Figures (rounded) in USD millions (Dec. 2009–Dec. 2010) Figures do not account or o-invoice discounts/rebates and can vary rom reported mr sales


S A D I

11.1 9.1

M , h t l a e H S M I : e c r u o S

56


2011 Rank


2010 Rx Sales

41

Watson

42

Lundbeck

43

Kyowa Hakko Kirin

44

Dainippon Sumitomo

45

Shionogi

46

Actavis

47

Hospira

48

Nycomed

49

Apotex

50

Stada

Corona, Caliornia [watson.com]

Copenhagen, Denmark [lundbeck.com]

Tokyo, Japan [kyowa-kirin.co.jp]

Osaka, Japan [ds-pharma.co.jp]

Osaka, Japan [shionogi.co.jp]

Hanarjörður, Iceland [actavis.com]

Lake Forest, Illinois [hospira.com]

Zurich, Switzerland [nycomed.com]

North York, Ontario, Canada [apotex.com]

Bad Vilbel, Germany [stada.de]


TOTALS:

(USD


Pharm Exec

2010 R&D spend


(USD Millions)

[USD billions]

$2.6

[27.0%]

$296

CNS generics [0.9]

$2.6

[–0.6%]

$542

Cipralex/Lexapro [1.5]

$2.6

[14.7%]

$429

Nesp/Espo [0.6*]

$2.6

[20.1%]

$554

Amlodin [0.6]

$2.4*

[35.2%]

$135

Crestor [0.3]

$2.4*

[32.5%]

N/A

$2.3

[13.3%]

$301

N/A [N/A]

$2.2

[–20.2%]

$281

Pantoprazole [1.2]

$2.1*

[–19.2%]

N/A

N/A [N/A]

$2.1

[–5.0%]

$73

Generic omeprazole [0.1]

estimates

2010: $593.4 billion


2009: $550.5 billion Sponsored by

www.dsm.com

Oxycodone [0.4]

* Estimate

Figures are rounded

7.79%

58


The Top 10 Year In Review 1. Pfzer President and CEO

4. Merck Elected Kenneth Frazier CEO.

Je Kindler retired, succeeded by Ian C. Read. George Lorch elected Non-Executive Chairman o the Board. Sutent approved in EU or treatment o pancreatic neuro-endocrine tumors. Launched Prevnar 13, a vaccine against 13 strains o pneumococcal diseases in inants and young children. Also has 118 products in the R&D pipeline and had 1,300 clinical trials in 2010.

Bought Inspire or $430 million. Rotateq vaccine awarded top honor at Prix Galien USA 2010. Merck BioVentures entered into an alliance with Parexel or biosimilar development. Signed commercialization agreement with Lundbeck or Sycrest and a letter o mutual intent with China’s Sinopharm. Pipeline has more than 20 late-stage candidates. Licensed oral mTOR inhibitor or multiple cancers rom Ariad. Oral hepatitis C protease inhibitor Boceprevir granted Priority Review status by FDA.

2. Novartis Completed purchase o Alcon rom Nestlé or $38.7 billion. Jonathan Symonds promoted to CFO. David Epstein replaced CEO Joe Jimenez as Division Head, Pharmaceuticals. Thirteen major pharmaceutical approvals in the US, Europe, and Japan, with 147 products in development. Tasigna was approved in the US, the EU, Japan, and Switzerland or patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), a orm o blood cancer. Menveo (vaccine against meningococcal disease) launched in the US, EU, and parts o Latin America and Asia. Sandoz launched generic enoxaparin, its most successul launch to date, and acquired Oriel Therapeutics.

5. Roche Rituxan approved in US as rst-line treatment or chronic lymphocytic leukemia (CLL) and relapsed/reractory CLL. Tarceva approved in US and EU or rst-line treatment o non-small-cell lung cancer ater chemotherapy. FDA rejected use o Avastin as a treatment or metastatic breast cancer; Roche has requested a hearing to appeal this decision. Daniel O’Day appointed COO o the Pharmaceuticals division. Alan Hippe named CFO. Jean-Jacques Garaud appointed Head o Roche Pharma Research and Early Development.

6. GlaxoSmithKline Benlysta 3. Sanof-Aventis Initiated acquisition o Genzyme or $16.6 billion (completed in April) and nished acquisition o OTC company Chattem. Began collaboration programs with Harvard and Columbia Universities and a research alliance with Scripps Genomic Medicine. Jevtana approved in US or second-line treatment o metastatic hormone-reractory prostate cancer.

(belimumab, the rst new lupus treatment in 60 years) approved by FDA in March. Six products in total approved by US and EU; seven more led with regulators. Malaria vaccine in Phase III trials in Arica, with 30 other late-stage assets. Julian Heslop retired as CFO, succeeded by Simon Dingemans. Patents or active ingredients in Seretide/Advair expired.

7. AstraZeneca Crestor substance patent upheld in US court. Approvals include Vimovo (naproxen/esomeprazole magnesium) in US and EU and Brilique (atherothrombotic event prevention) in

EU. Kombiglyze XR, the only once-daily dose o DPP4/metormin, developed with Bristol-Myers Squibb, also approved in US. Nine molecules in Phase III trials or submitted or regulatory approval, with another 92 projects in development. Completed deal with Rigel or development o ostamatinib (rheumatoid arthritis).

8. Johnson & Johnson Completed tender oer or Crucell N.V. in February 2011; acquired 98.93 percent o shares. Products under regulatory review include: Rivaroxoban or stroke prevention in patients with atrial brillation (US), Telaprevir or hepatitis C (US and EU), Abiraterone acetate or metastatic advanced prostate (US and EU), and rilpivirine or HIV. Eight more candidates planned or regulatory submission rom 2011 to 2013.

9. Eli Lilly Completed acquisition o Alnara and Avid Radiopharmaceuticals. Launched statin Livalo in the US with partner Kowa. Has 68 molecules in development. Several monoclonal antibodies or cancer in late-stage development. Phase III candidates include Necitumumab or non-small-cell lung cancer and Ramucirumab or metastatic breast and gastric cancers. Signed commercialization deal with Acrux or newly approved experimental testosterone solution Axiron.

10. Abbott The year was marked by acquisitions, including the pharmaceutical business o Solvay or $6.1 billion plus milestones, and Piramal Healthcare’s Healthcare Solutions business, a leader in the Indian branded generics market, or $2.2 billion in cash, plus $1.6 billion in annual payments through 2014. Additional acquisitions included Advanced Medical Optics, STARLIMS Technologies (inormatics), and the remaining shares o Facet Biotech.

About the Authors Jerry Cacciotti is a Partner in Oliver Wyman’s Health and Lie Sciences Practice. He can be reached at [email protected]

Patrick Clinton is Marketing Director in the Health & Lie Sciences practice o Oliver Wyman. He can be reached at [email protected]


Pharmaceutical Executive Top 50 Pharma Companies Report

Recommend Documents